SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MCRB

Seres Therapeutics, Inc. (NASDAQ:MCRB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.24-$0.09 (-6.77%)
 
Market cap
$12.6M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 26, 2015
Market Cap$12.64M-92.7%
Revenue (ttm)$2.13M+505.4%
Net Income-$46.95M-970.5%
EPS-$4.95-911.5%
Shares Out10.20M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume56,761
Open$1.36
Previous Close$1.33
Day's Range$1.22 - $1.37
52-Week Range$1.20 - $18.86
Beta0.21
AnalystsBuy
Price Target$12.00(+867.74%)
Earnings DateMar 11, 2027
-6.02% (1D)
No price history available.

About MCRB

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.

Address
101 Cambridgepark Drive, Cambridge, MA, 02140, US
Market Cap
13 million
Employees
66
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$9.54K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Distressed
From MCRB’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-6.77%
5 Days
-10.14%
1 Month
-41.78%
6 Months
-84.34%
1 Year
-92.69%

$MCRB stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MCRB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MCRB's directors and management

Net Shares Purchased by Insiders−600−30002025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MCRB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New MCRB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MCRB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MCRB

VTIVanguard Morningstar Total Stock Market ETF$287.57K
VXFVanguard Extended Market ETF$134.25K
IWCiShares Micro-Cap ETF$30.66K
EESWisdomTree U.S. SmallCap Fund$23.72K
PRFZInvesco RAFI US 1500 Small-Mid ETF$16.67K
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF$10.00K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MCRB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
14
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

STSBiShares Factors US Small Blend Style ETF0.08%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.01%

Weight is the stock’s share of each fund’s holdings.